Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Bevacizumab vs Sorafenib in Untreated Advanced HCC (China)
CTR20180665Phase 3Completed
- Sponsor
- Roche
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab, bevacizumab, sorafenib in hepatocellular carcinoma (HCC), sponsored by Roche. Started May 2018; status: completed.
02
Drugs
atezolizumabbevacizumabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20180665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180665.